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PEY8
WHEN IS IT COST-EFFECTIVE TO TREAT OCULAR
HYPERTENSION? RESULTS OF A DECISION-ANALYTIC
HEALTH ECONOMIC MODEL
Stewart WC1, Stewart JA1, Nassar Q1, Mychaskiw MA2
1Pharmaceutical Research Network, LLC, Charleston, SC, USA, 2Pﬁzer
Inc, New York, NY, USA
OBJECTIVE: To assess the cost-effectiveness of treating ocular
hypertension (OHT) in the United States. METHODS: Cost-
effectiveness was estimated using a Markov model. Health states
were stable and progressed OHT. Data from the Ocular Hyper-
tension Treatment Study (OHTS) were used to derive practice
patterns and transition probabilities. Data were obtained from
Blue Cross/Blue Shield for speciﬁc unit costs for medications,
patient visits, diagnostics, and therapeutic procedures. A payer
perspective was adopted, the time horizon was 5 years, and costs
were discounted at 3% per year. RESULTS: Across all OHT
patients, the incremental cost-effectiveness ratio (ICER) was
$89,072 to prevent 1 case from progressing to primary open-
angle glaucoma. After adjusting for risk factors for progression
identiﬁed in multivariate analysis in the OHTS trial, minimally
cost-effective ICERs were: 20 years above the mean age of 56
years, ICER = $45,155; 4 mmHg above the mean intraocular
pressure of 25 mmHg, ICER = $46,748; 40 microns less than the
mean central corneal thickness of 573 microns, ICER = $36,683;
and 0.2 wider than the mean vertical cup/disc ratio of 0.4, ICER
= $35,633. CONCLUSIONS: This Markov model was based on
the results and practice patterns of the OHTS trial, and the
results suggest that treating all OHT patients may not be cost
effective. However, treating OHT patients with risk factors for
progression, i.e., advancing age, higher intraocular pressures,
thinner central corneal thicknesses, and wider vertical cup/disc
ratios, does appear to be cost-effective in preventing the onset of
glaucomatous damage.
PEY9
ASSESSMENT OF THE COST-EFFECTIVENESS OF
TRAVOPROST VERSUS LATANOPROST,AS SINGLE AGENTS
FOR GLAUCOMA TREATMENT IN FRANCE
Payet S1, Berdeaux G2, Launois R1
1REES, Paris, France, 2Alcon France, Rueil-Malmaison, France
OBJECTIVES: To assess the cost-effectiveness of travoprost
versus latanoprost as single agents to treat glaucoma in France.
METHODS: A Markov model reproduced the course, over 5
years, of patients beginning a prostaglandin as monotherapy
(PM). The effectiveness criterion was ‘mean time to treatment
change’ (MTTC), ﬁtted with a Weibull distribution from a
national survey. Possible switches were association (A), treat-
ment substitution (TS) and laser treatment or surgery (LS). After
LS, patients could remain without treatment or proceed to PM
or TS. Stratiﬁcation used intra-ocular pressure (IOP) at treatment
onset: ≤20 mmHg, 21 to 23 mmHg and ≥24 mmHg. Transition
probabilities and costs per treatment line were extracted from
two French observational databases. Bootstrap techniques were
implemented to drive the probabilistic sensitivity analyses.
RESULTS: MTTC was 44.3 months for travoprost and 37.7 for
latanoprost. Additional costs for Travatan were €52, leading to
an ‘incremental cost-effectiveness ratio’ (ICER) without treat-
ment change of €95 per year. 1.9% of patients treated with
latanoprost underwent laser treatment or surgery, compared to
1.2% with travoprost. Results varied with baseline IOP values
(≤20, 21 to 23, ≥24 mmHg) such that 55.6%, 53.9% and 50.4%
of patients, respectively, remained under travoprost treatment
when simulation ended, compared to 32.3%, 26.1% and 26.1%
under latanoprost. Thus ICERs, without treatment change, were
€140, €45, and €123 per year, respectively. CONCLUSION:
Travoprost yielded a longer effectiveness proﬁle and minimized
early treatment regimen changes. The smaller portion of patients
needing a new treatment, laser treatment or surgery virtually
compensated for the higher travoprost acquisition cost. Travo-
prost is a more cost-effective alternative, especially in patients
whose IOP at treatment onset lay between 21 and 23 mmHg.
PEY10
COST-EFFECTIVENESS OF TWO TREATMENT SEQUENCES IN
GLAUCOMA TREATMENT: XALATAN®-XALACOM® VERSUS
TRAVATAN®-DUOTRAV®
Maurel F1, Le pen C1, Berdeaux G2
1Aremis, Neuilly sur Seine, France, 2Alcon France, Rueil-Malmaison,
France
OBJECTIVES: To compare the costs and effectiveness of two
treatment sequences, Xalatan®-Xalacom® (X-X) versus Tra-
vatan®-DuoTrav® (T-D), in the treatment of glaucoma or ocular
hypertension (OHT). METHODS: A discrete event simulation
(DES) model was constructed. Patients with either glaucoma or
OHT were treated ﬁrst-line with a prostaglandin, either
Xalatan® or Travatan®. In case of treatment failure, patients
were switched to the speciﬁc prostaglandin-timolol sequence
Xalacom® or DuoTrav®. Failure was deﬁned as intraocular
pressure higher than 18 mmHg (Advanced Glaucoma Interven-
tion Study) at 2 visits. “Time to failure” was estimated from 
two randomized clinical trials (Xalatan® versus Travatan®,
Xalacom® versus DuoTrav®). Log-rank tests were computed.
Exponential functions were used to model “time to failure”. The
economic perspective was that of society in France. The time
horizon of the model was 60 months. Resource utilizations were
estimated from a national French observational survey. Out-
comes included treatment failure and disease progression. Sensi-
tivity analyses were performed. RESULTS: Xalatan® treatment
resulted in more treatment failures than Travatan® (p < 0.007),
and Xalacom® more than DuoTrav® (p < 0.04). At 60 months,
the probability of starting a third treatment line was 39.0% with
X-X versus 25.1% with T-D. On average, X-X patients devel-
oped 0.51 new visual ﬁeld defects versus 0.43 for T D patients.
The probability of no disease progression at 60 months was
64.2% with X-X and 69.2% with T-D. The 5-years costs of X-
X and T-D patients were 3220 euros and 3184 euros, respec-
tively (Travatan® price was 114% Xalatan®; Xalacom® 
and DuoTrav® prices were hypothesized as equal). CONCLU-
SIONS: Based on well-controlled randomized clinical trial results
and using a DES model, the T-D sequence was economically
dominant over the X-X sequence.
PEY11
MODELING THE COST AND CONSEQUENCES OF RESTOR®,A
MULTIFOCAL INTRAOCULAR LENS (IOL) IN REFRACTIVE
SURGERY IN FRANCE
Berdeaux G1, Lafuma A2, Guelfucci F3
1Alcon France, Rueil-Malmaison, France, 2Cemka-Eval, Bourd-la-Reine,
France, 3Cemka-Eval, Bourg-la-Reine, France
OBJECTIVE: To model the lifetime costs and consequences of
wearing spectacles versus implantation of ReSTOR® (a multi-
focal IOL), or other multifocal IOLs (MFIOLs), in the treatment
of presbyopia. METHODS: A Markov model followed subjects
from age 45 (presbyopia onset) to death. The prevalence rates of
patients without spectacles after ReSTOR® surgery and other
MFIOLs were taken from clinical trials. The number of cataract
operations avoided by presbyopia surgery (PS) and mortality
prevalence rates were estimated from national statistics.
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Resource utilization included surgical procedures, implants,
spectacles, visits to ophthalmologists and eye-centers, trans-
portation, and time lost by patients. Discount rates and sensi-
tivity analyses were performed. Two perspectives were
considered: Sickness Fund (SF) and Societal. RESULTS: Specta-
cle-free rates were >80% for ReSTOR® and 40% for MFIOLs.
Mean lifetime numbers of spectacles purchased were 4.2 with
ReSTOR®, 12.7 with MFIOLs, and 21.3 without PS. Early PS
avoided 0.80 late cataract surgeries per subjects. Surgical proce-
dure costs were €3292 for ReSTOR® and €2292 for other
MFIOLs, respectively. From the societal perspective, total undis-
counted costs for ReSTOR® were €5268, €7170 for other
MFIOLs, and €8492 without PS. With a 3% discount rate, these
costs were €4569, €5071 and €4244, respectively. From the SF
perspective, total undiscounted costs were €146 with ReSTOR®,
€437 with MFIOLs, and €1.688 without PS. With a 3% discount
rate, these costs were €76, €227 and €747, respectively. 
CONCLUSION: PS should decrease the undiscounted costs 
of vision care from both perspectives. For SF it is highly beneﬁ-
cial while PS remains unlisted for reimbursement. For Society,
the discounted incremental cost of avoiding spectacles at age 45
was less than €9/year. ReSTOR® improves patients’ lifestyle and
is a cost-effective alternative versus spectacles in presbyopic
patients.
PEY12
MODELING THE COSTS AND CONSEQUENCES OF RESTOR®,
A MULTIFOCAL INTRAOCULAR LENS (IOL),AFTER
CATARACT SURGERY IN FRANCE
Berdeaux G1, Lafuma A2, Guelfucci F3
1Alcon France, Rueil-Malmaison, France, 2Cemka-Eval, Bourd-la-Reine,
France, 3Cemka-Eval, Bourg-la-Reine, France
OBJECTIVE: To compare the lifetime costs and consequences of
liberating patients from spectacles, after cataract surgery, by
implanting the multifocal IOL “ReSTOR®” versus monofocal
IOLs. METHODS: A Markov model was created to follow
patient cohorts from cataract surgery until death. Prevalence
rates of patients not needing spectacles after cataract surgery
were obtained from a clinical trial. Resource utilization included
implant surgery, IOLs, spectacles, visits to ophthalmologists and
eye centers, transportation, and time lost by patients. Economic
perspectives were those of Society and Sick Funds (SF). Mortal-
ity rates were introduced into the model. Discount rates were
applied. Sensitivity analyses were performed. Patients were fol-
lowed from age 70 to 100 years. RESULTS: More than 80% of
patients implanted with ReSTOR® were spectacle-free com-
pared to about 10% with monofocal IOLs. The mean number
of spectacles purchased was 1.7 after ReSTOR® and 7.6 after
monofocal IOLs. Surgical costs were €3292 for ReSTOR® and
€2292 for monofocal IOLs. From the societal perspective, total
undiscounted cost estimates were €4384 with ReSTOR® com-
pared to €5359 with monofocal IOLs. With a 3% discount rate
these costs became €4226 and €4654, respectively. From the SF
perspective, total undiscounted cost estimates were €2350 with
ReSTOR® and €2553 with monofocal IOLs. With a 3% dis-
count these costs became €2334 and €2481, respectively. Costs
and intervals between spectacle replacements were the most sen-
sitive parameters. CONCLUSION: From both the societal and
SF perspectives, undiscounted savings achieved by liberating
patients from spectacles counterbalanced the initially higher cost
of ReSTOR®. For Society, the discounted incremental cost of
avoiding spectacles after ReSTOR® implants was less than
€13/year, and SF saved money. ReSTOR® improves patients’
lifestyle and is a cost-effective alternative versus spectacles in
patients requiring cataract surgery.
PEY13
LAST STAGE GLAUCOMA IN EUROPE: COSTS AND QUALITY
OF LIFE OF PATIENTS FROM 4 COUNTRIES
Aagren M1,Arnavielle S2, Bron A2,Thygesen J3, Baggesen K4,
Azuara-Blanco A5, Neville S5, Buchholz P6
1MUUSMANN Research & Consulting, Copenhagen, Denmark,
2University Hospital Dijon, Dijon, France, 3Rigshospitalet, Copenhagen,
Denmark, 4County of Northern Jutland, Aalborg SV, Denmark,
5Aberdeen University Hospital, Aberdeen, Scotland, UK, 6Allergan
Europe, Ettlingen, Germany
BACKGROUND: European studies have identiﬁed primary
open angle glaucoma (POAG) as the second leading cause of
blindness, accounting for 8–10% of blindness in older people.
The objective of this study was to estimate the societal costs and
the quality of life among patients with late stage POAG.
METHODS: Charts of late stage POAG patients in France,
Germany, the UK and Denmark were reviewed and the patients
were interviewed. Costs and utility values of health related
quality of life were estimated (based on resource use multiplied
with unit costs and on EQ-5D questionnaire). RESULTS: 162
patients were included. Average level of visual acuity was 0.28
and 0.11 of the best and worst eye, respectively. Annual health
maintenance costs of late stage glaucoma patients are €830 (SD:
€445). This does not include costs of surgery and larger proce-
dures. Purchase costs of devices amount to €2045 per patient.
Most importantly, however, are costs of home care, which
average €2703 per year. With respect to the health related quality
of life the average score is 0.67 and best predictor of QoL is
visual acuity of the patients’ best eye (negatively correlated, p =
0.005). Best eye visual acuity is also negatively correlated with
health care maintenance costs (p = 0.024). With respect to home
care costs the correlation is positive but not signiﬁcant. CON-
CLUSIONS: This study shows that late stage glaucoma is asso-
ciated with considerable health care and—in particular—social
care costs (home care). It is an important ﬁnding that mainte-
nance health care costs is negatively correlated with visual acuity
(and thereby QoL). A lower visual acuity is predictive of lower
QoL.
PEY14
BIMATOPROST, LATANOPROST,AND TRAVOPROST FOR THE
TREATMENT OF GLAUCOMA:A COST-EFFECTIVENESS
ANALYSIS IN SCANDINAVIA USING A DECISION-ANALYTIC
HEALTH ECONOMIC MODEL
Stewart WC1, Stewart JA1, Passmore CL1, Mychaskiw MA2
1Pharmaceutical Research Network, LLC, Charleston, SC, USA, 2Pﬁzer
Inc, New York, NY, USA
OBJECTIVE: To assess the cost-effectiveness of bimatoprost,
latanoprost, and travoprost monotherapy in patients with open-
angle glaucoma in Denmark, Norway, and Sweden (Scandi-
navia). METHODS: Cost-effectiveness analysis was performed
using a Markov decision-analytic health economic model with
stable and progressed glaucoma as the health states. Transition
probabilities for primary open-angle and exfoliation glaucoma
were derived from published medical literature, and information
regarding clinical practice patterns was obtained from surveys
completed by 45 ophthalmologists dispersed throughout each of
the countries. Country-speciﬁc unit costs were used for medica-
tions, clinic visits, diagnostics, and outpatient services. Quality
of life weights for various levels of visual acuity ranged from 0.50
to 0.68, and the effectiveness metric was the quality-adjusted life
year (QALY). A 5-year time horizon was adopted, analyses were
from a payer perspective, and costs were discounted at 3% per
year. RESULTS: Effectiveness (years till progression) was within
a narrow range (3.2048 to 3.2613 QALYs) across all products
